- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CCHIT Ending Testing and Certification of EHRs
The Certification Commission for Health Information Technology is getting out of the business of testing and certifying electronic health-record systems after nearly a decade as the first and still most-commonly used provider of those services in the U.S.
The Certification Commission for Health Information Technology is getting out of the business of testing and certifying electronic health-record systems after nearly a decade as the first and still most-commonly used provider of those services in the U.S.
The organization also stopped taking applications for testing and certification services from vendors Tuesday and will finish work on about 70 of those systems it has in the pipeline and wind down that part of its operations by April or May, CCHIT Executive Director Alisa Ray said.
Today, roughly half of all health IT systems on the official Certified Health IT Product List kept by the Office of the National Coordinator for Health Information Technology at HHS have been tested and certified by CCHIT.
Read the full story here: http://bit.ly/1hNsNzB
Source: Modern Healthcare
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Optune Lua Device in NSCLC
October 16th 2024Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.
Read More
